The second- and third-generation CAR-T cells incorporate 4–1BB or CD28 co-stimulatory molecules together with CD3ζ, significantly enhancing the anti-tumor effects of the cells, as well as the persistence and proliferation of the CAR-Ts in vivo (10). This evidence concerns the gene CD28 and neoplasm.